Is CD47 a good target for immunotherapy in lymphoma?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Steven Horwitz, Memorial Sloan Kettering Cancer Center, New York, US. We asked, Is CD47 a good target for immunotherapy in lymphoma?
Horwitz discusses the unmet need for immunotherapy in lymphoma, and whether targeting CD47 could be a viable treatment strategy. He also gives an overview of early safety and efficacy data and outlines future research for CD47 targeting.
Dr. Horwitz has consulted, received honorarium from, or participated in advisory boards for; Acrotech Biopharma, C4 Therapeutics, Janssen, Kura Oncology, Kyowa Hakko Kirin, Myeloid Therapeutics, ONO Pharmaceuticals, Seattle Genetics, Takeda, Trillium Therapeutics, and Vividion Therapeutics.
Dr. Horwitz has received research support for clinical trials from ADC Therapeutics, Affimed, Aileron, Celgene, Daiichi Sankyo, Forty Seven, Inc., Kyowa Hakko Kirin, Millennium /Takeda, Portola Pharmaceuticals, Seattle Genetics, Trillium Therapeutics, and Verastem.
Видео Is CD47 a good target for immunotherapy in lymphoma? канала Lymphoma Hub
Horwitz discusses the unmet need for immunotherapy in lymphoma, and whether targeting CD47 could be a viable treatment strategy. He also gives an overview of early safety and efficacy data and outlines future research for CD47 targeting.
Dr. Horwitz has consulted, received honorarium from, or participated in advisory boards for; Acrotech Biopharma, C4 Therapeutics, Janssen, Kura Oncology, Kyowa Hakko Kirin, Myeloid Therapeutics, ONO Pharmaceuticals, Seattle Genetics, Takeda, Trillium Therapeutics, and Vividion Therapeutics.
Dr. Horwitz has received research support for clinical trials from ADC Therapeutics, Affimed, Aileron, Celgene, Daiichi Sankyo, Forty Seven, Inc., Kyowa Hakko Kirin, Millennium /Takeda, Portola Pharmaceuticals, Seattle Genetics, Trillium Therapeutics, and Verastem.
Видео Is CD47 a good target for immunotherapy in lymphoma? канала Lymphoma Hub
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Why should we use checkpoint inhibitors with CAR-T therapy in DLBCL?
Meet Prof. Simon Rule of Derriford Hospital in Plymouth, UK
What are the promising updates in lymphoma at ASH 2019?
Prof. Gilles Salles | EBMT 2018 | Émergence de la thérapie cellulaire CAR-T dans les lymphome
Neurotoxicity from CAR T-cell therapy: why does it happen?
Case study Q&A: What is the optimum treatment in DLBCL?
What is in the pipeline for the treatment of T-cell lymphoma?
Astrid Pavlovsky | EHA 2018 | Key highlights from EHA on Hodgkin lymphoma
Satellite Symposium | Patient with R/R DLBCL— US perspective
Obinutuzumab based induction and maintenance in 1st line FL patients results of the Phase 3 GALLIU
Satellite Symposium | Roundtable discussion, summary, and conclusions
What does the first-line data for polatuzumab vedotin tell us about its role in R/R DLBCL?
Jean-Marie Michot| Key safety & efficacy outcomes of CC-122 & obinutuzumab study in R/R B-cell NHL?
The challenges for women in lymphoma: where there's a WiL, there's a way
Prof. Judith Trotman | ASH 2017 | BRIGHT study results
Astrid Pavlovsky explains why you should join the virtual Lymphoma Hub Satellite Symposium
What is the most promising novel agent for the treatment of aggressive B-cell lymphoma?
Case study: Follicular lymphoma: watch and wait
Clinical implications of the ODAC vote in favor of polatuzumab vedotin for untreated DLBCL.
How might CAR T-cells change the treatment landscape for patients with CLL?
How will CAR T therapy for lymphoma be used in the future?